Merck & Co., Inc., known as MRK in the stock exchange, is a globally recognized pharmaceutical organization that is dedicated to addressing some of the biggest health challenges around the world. Founded in 1891 as a subsidiary of the German company Merck, which was established in 1668, Merck & Co. has since become a separate and independently operated company since WW1. Headquartered in Kenilworth, New Jersey, USA, this multinational organization is on the frontline in the development, manufacturing, and delivery of innovative health solutions that improve health outcomes for people worldwide.
Over the years, Merck & Co. has evolved into one of the largest pharmaceutical companies operating across four primary divisions: Pharmaceuticals, Animal Health, Healthcare Services, and Alliances. With a robust portfolio of medicine therapies, vaccines, biologic therapies, animal health, and consumer care products, the company holds a leading position in several therapeutic areas, including oncology, cardiovascular diseases, diabetes, and infectious diseases.
Following a research-driven approach, Merck & Co invests heavily in Research & Development (R&D), aiming to discover and develop innovative health solutions. Its R&D strategy focuses on harnessing breakthrough science in areas that will considerably impact health and well-being, thus improving human and animal health worldwide.
Notably, Merck & Co. made significant contributions towards the development of therapies for HIV and AIDS, and more recently, it played a significant role in the battle against the global pandemic, contributing to the manufacturing of the Johnson & Johnson COVID-19 vaccine.
On the corporate social responsibility front, Merck & Co. is committed to improving access to healthcare. Its Merck for Mothers program, launched in 2011, has significantly reduced maternal mortality rates in several parts of the globe by ensuring safe pregnancy and childbirth.
Its position on sustainability is clear and it is committed to making a positive impact on global health and the environment while ensuring its business sustainability. It focuses on areas such as product responsibility, environmental sustainability, employee health and safety, and ethical sourcing and human rights.
Through unmatched innovation, strategic collaborations, and a commitment to sustainably improving global health, Merck & Co., Inc. continues to play a vital role in the global pharmaceutical sector. As of 2022, the company remains an essential player in addressing public health challenges and develops therapies that address previously unmet medical needs, thereby driving the advancement of healthcare and enriching lives worldwide.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Merck and Daiichi Sankyo have withdrawn their FDA application for ifinatamab deruxtecan, a small cell lung cancer drug, citing that the Phase 2 data did not meet accelerated approval requirements. Despite the withdrawal, the companies are continuing enrollment for a randomized Phase 3 lung cancer trial, which is nearing completion. They aim to file a new application based on the results of the Phase 3 trial.
Merck and Daiichi Sankyo have withdrawn their US application for accelerated approval of their experimental lung cancer therapy, ifinatamab deruxtecan. The decision followed discussions with the US Food and Drug Administration, which determined that mid-stage clinical study data did not meet the requirements for an early green light. The therapy was intended for adults with extensive-stage small cell lung cancer that had worsened after standard chemotherapy.
REGENXBIO Inc. reported new three-year follow-up data from its ALTITUDE trial, showing that six out of ten higher-dose participants experienced a significant improvement in diabetic retinopathy severity. This data supports the ongoing Phase IIb/III NAAVIGATE trial, which is testing the gene therapy sura-vec against a sham control. The company expects topline results from its ATMOSPHERE and ASCENT trials for wet age-related macular degeneration in Q4 2026 and projects a cash runway into Q4 2027.
Celldex Therapeutics, Inc. (CLDX) is drawing market attention after its barzolvolimab studies in chronic spontaneous urticaria met primary and key secondary endpoints. This development highlights the company's operating priorities and its position within the Healthcare Stocks sector. Investors are now focused on consistent execution and how these positive clinical results translate into sustained operational success and customer response.
Moderna (NASDAQ: MRNA) shares reached a new 52-week high of $198 due to anticipation surrounding upcoming clinical trial data for its experimental cancer treatment, intismeran autogene. The company's headline abstract on late-stage trial results for intismeran combined with Merck's Keytruda in melanoma patients has been accepted for the European Society for Medical Oncology Congress. Despite the rally and promising trial results, Bernstein SocGen Group maintained a "Market Perform" rating and a $45 price target, expressing skepticism about the stock's current valuation.
Merck has received FDA approval for its combination therapy of Welireg and Lenvima, enhancing its presence in the renal cell carcinoma (RCC) treatment pathway. This move reinforces Merck's strategy in oncology, particularly as it looks to a future beyond Keytruda's patent expiration. The approval further solidifies Welireg's potential in broader kidney cancer indications.
Moderna, Inc. (MRNA) stock surged nearly 7% to a 52-week high of $194.82, displaying a strong bullish trend above all major moving averages. However, technical indicators like the daily RSI14 at 75.12 and price trading above the upper Bollinger Band suggest the stock is overbought and may be due for a pause or consolidation. While the overall trend remains bullish, short-term momentum on hourly charts shows signs of cooling, warranting disciplined positioning.